Market capitalization | $5.69m |
Enterprise Value | $-1.15m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.39 |
EV/Sales (TTM) EV/Sales | -0.46 |
P/S ratio (TTM) P/S ratio | 2.26 |
P/B ratio (TTM) P/B ratio | 0.81 |
Revenue growth (TTM) Revenue growth | 7.15% |
Revenue (TTM) Revenue | $2.52m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
1 Analyst has issued a forecast Xenetic Biosciences, Inc.:
1 Analyst has issued a forecast Xenetic Biosciences, Inc.:
Sep '24 |
+/-
%
|
||
Revenue | 2.52 2.52 |
7%
7%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -4.36 -4.36 |
10%
10%
|
EBIT (Operating Income) EBIT | -4.36 -4.36 |
10%
10%
|
Net Profit | -4.08 -4.08 |
8%
8%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Xenetic Biosciences, Inc. engages in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient's malignant tumor cells. Its product pipeline includes XCart Platform and Polyxen. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.
Head office | United States |
CEO | James Parslow |
Employees | 4 |
Founded | 2011 |
Website | www.xeneticbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.